麻豆传媒

News, features, and commentary about cancer-related issues

USPSTF screening recommendations, broader indication for ribociclib, OS win for pembrolizumab

ProSense device would be indicated with adjuvant endocrine therapy for some low-risk patients

News, features, and commentary about cancer-related issues

PD-1/PD-L1 inhibitors singled out for association

News, features, and commentary about cancer-related issues

Largest survival benefit observed in patients who entered a cessation program within 6 months

Large cohort study showed cancer risk increased with exposure to fine particulate matter

News, features, and commentary about cancer-related issues

Study also showed that patients were more likely to receive timely treatment

-- News, features, and commentary about cancer-related issues

Absolute risk remains low, however

Trials now enroll lower-risk women who get better treatment, analysis suggests

Adding inavolisib to palbociclib/fulvestrant more than doubled PFS in endocrine-resistant disease